Scientists hailed the results

Scientists hail ‘incredible’ results of diabetes vaccine that lowers blood sugar twice as fast

Millions of diabetics could see life-changing results from an ‘incredible’ new drug, researchers have suggested today.

Tirzepatide works by mimicking hormones that help both control blood sugar and suppress appetite, helping people lose weight.

It has already been shown to be more effective than other similar drugs, including those distributed by the NHS.

But new data, to be presented at a medical conference, will reveal that it also works up to 12 weeks faster.

Scientists involved in the analysis said the once-a-week shot produced results “beyond anything we currently have”.

Tirzepatide mimics hormones in the body that help people feel full and satisfied after a meal.

These are often at low levels in obese patients, who tend to make up the majority of type 2 diabetics.

In addition to helping people feel full, the drug helps control diabetes by helping the body avoid sugar crashes, removing excess sugar from the body, and preventing the liver from making and releasing too much. sugar.

Uncontrolled diabetes can lead to blindness and leave patients with limb amputations or comas.

Scientists have hailed the ‘incredible’ weight loss and diabetes management results of a clinical trial of tirzepatide, sold under the Mounjaro brand

What is type 2 diabetes?

Type 2 diabetes is a common condition that causes blood sugar (glucose) levels to get too high.

It can cause symptoms like excessive thirst, the need to urinate a lot, and fatigue. It can also increase your risk of serious eye, heart, and nerve problems.

It is a permanent condition that can affect your daily life. You may need to change your diet, take medication, and have regular checkups.

It is caused by problems with a chemical in the body (hormone) called insulin. It is often linked to being overweight or inactive, or a family history of type 2 diabetes.

Source: ENM

Obesity rates have skyrocketed in recent decades, as has type 2 diabetes.

Figures now suggest around 5million Britons have the disease, along with 29million people in the US.

Drugs now exist to fight the disease, but the new analysis suggests that tirzepatide, sold under the brand name Mounjaro and made by US pharmaceutical company Eli Lilly, may offer better and faster improvements for sufferers.

The new data comes from two trials, which compared a 5mg, 10mg or 15mg dose to two different existing drugs.

Tirzepatide doses were increased by 2.5 mg every four weeks until the required strength was reached, then maintained for the duration of the trials lasting nearly a year.

One trial involved nearly 1,500 people with type 2 diabetes.

Participants in this trial were randomly assigned to receive one of three different doses of tirzepatide once a week or a daily injection of insulin.

The other trial compared the three doses of tirzepatide to another weekly dose for weight loss and diabetes called semaglutide. It brought together 1,800 participants.

Tirzepatide recipients achieved a key blood sugar control milestone of having hemoglobin A1c below 7%, on average four weeks faster than those on semaglutide.

It also outperformed daily insulin injections, with participants taking tirzepatide recording hemoglobin A1c levels below 6.5% 12 weeks earlier.

Similar results were also recorded for weight loss in the semaglutide trial.

Weekly dose of obesity cuts diabetes risk in half and may trigger enough weight loss, research finds

An obesity drug given in weekly injections more than halves the risk of developing type 2 diabetes, a landmark study has found.

Patients can inject themselves with semaglutide, which works by hijacking the brain to suppress appetite and reduce calorie intake.

Overweight and obese participants receiving the regular doses saw their odds of suffering from the disease drop by up to 61%.

The drug, called Wegovy, was approved for use in England after it was shown to help patients lose an average of 15% of their body weight, or 2 pounds.

Around 4.5million people live with type 2 diabetes in England, costing the NHS more than £10billion a year.

The researchers performed a new analysis of data from two previous trials of semaglutide to assess its impact on the disease.

Study leader Dr Timothy Garvey said an average weight loss of 15% was “sufficient to treat or prevent a wide range of complications of obesity that negatively affect the health and quality of life”. He added that this effect is “a game-changer in obesity medicine.”

People receiving the 10 mg and 15 mg doses of tirzepatide lost 5% of their total weight after 12 weeks.

This was half the time compared to semaglutide participants.

The lead author of the review, Dr Adie Viljoen, consultant metabolic physician and chemical pathologist at the East and North Hertfordshire NHS Trust, said tirzepatide produced “incredible” results.

“The speed we are seeing in lowering blood sugar and losing weight is beyond anything we have right now,” he said.

“It can put adults with type 2 diabetes in a better position to prevent long-term complications.

“Even a modest weight loss of 5% of baseline body weight is associated with clinically significant improvements in weight-related health problems for many people.

“For people with type 2 diabetes, to be able to achieve these health improvements in about half the time is pretty amazing.”

However, he added that it was important to remember that the injection was not a magic bullet and should be used alongside diet and exercise.

Type 2 diabetes occurs when the body does not produce enough insulin or when the insulin it produces does not work properly, leading to high blood sugar.

This can lead to serious health issues like heart disease, increased risk of stroke, kidney problems, eye disease, and nerve damage.

Unlike type 1 diabetes, which is genetic, type 2 diabetes is primarily caused by obesity. It is also reversible with a healthy lifestyle.

Tirzepatide mimics two hormones in the body, one called glucagon-like peptide-1 (GLP-1) receptor agonists and glucose-dependent insulinotropic peptide, or GIP.

GLP-1 receptor agonists have been used for about a decade and have transformed the treatment of type 2 diabetes.

Participants in clinical trials have reported experiencing nausea, vomiting, and diarrhea as side effects of taking tirzepatide, although these were most commonly reported when doses were increased.

The drug is currently approved as a prescription diabetes drug in the United States, although it has been speculated that Eli Lilly will seek approval for use as a weight-loss drug.

It would cost around £843 ($975) for a four-week course, but is currently not approved for use in the UK.

The authors of the latest analysis noted several limitations of their study, such as clinical trials not being specifically designed to compare the rate of glycemic control and weight loss between drugs, and therefore the results should be interpreted with caution. .

The analysis, funded by Eli Lilly, will be presented at the European Association for the Study of Diabetes conference in Sweden September 19-23.

#Scientists #hail #incredible #results #diabetes #vaccine #lowers #blood #sugar #fast

Leave a Comment

Your email address will not be published.